Nanoparticles containing nitric oxide donor with antileishmanial agent for synergistic effect against visceral Leishmaniasis

Journal of Biomedical Nanotechnology

Volumn 7, Issue 1, 2011, Pages 213-215

  Pandya, Sanket ^a   Verma, Rahul K ^b   Misra, Amit ^b  

^a National Institute of Pharmaceutical Education and Research (NIPER)   (India)

^b CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

Doxorubicin; Leishmaniasis; Nanoparticles (NP); Nitric oxide donors; Phagocytosis; Reticuloendothelial

Indexed keywords

DOXORUBICIN; LEISHMANIASIS; NITRIC OXIDE DONORS; PHAGOCYTOSIS; RETICULOENDOTHELIAL;

ANTIGEN-ANTIBODY REACTIONS; DRUG PRODUCTS; NANOPARTICLES; SODIUM;

NITRIC OXIDE;

ANTILEISHMANIAL AGENT; DOXORUBICIN; NANOPARTICLE; NITRIC OXIDE DONOR; NITROPRUSSIDE SODIUM; POLYGLACTIN; ANTIPARASITIC AGENT; NANOCAPSULE;

ARTICLE; DRUG ACTIVITY; IN VITRO STUDY; INFRARED SPECTROSCOPY; PARTICLE SIZE; SUSTAINED DRUG RELEASE; THIN LAYER CHROMATOGRAPHY; VISCERAL LEISHMANIASIS; ZETA POTENTIAL; CHEMISTRY; DRUG COMBINATION; DRUG FORMULATION; DRUG POTENTIATION; HUMAN; METHODOLOGY; ULTRASTRUCTURE;

ANTIPARASITIC AGENTS; DOXORUBICIN; DRUG COMBINATIONS; DRUG COMPOUNDING; DRUG SYNERGISM; HUMANS; LEISHMANIASIS, VISCERAL; NANOCAPSULES; NITRIC OXIDE DONORS; NITROPRUSSIDE;

EID: 79957787229     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2011.1274     Document Type: Article

References (4)

1. C. E. Greene, Infectious Diseases of the Dog and Cat, WB Saunders Co, Philadelphia, Philadelphia, USA (2006), p. 9.
2. S. K. Carter, Adriamycin-a review, J. Natl. Cancer Inst. 55, 1265 (1975).
3. P. López-Jaramillo, C. Ruano, J. Rivera, E. Terán, R. Salazar-Irigoyen, and S. Moncada, Treatment of cutaneous leishmaniasis with nitric-oxide donor. Lancet. 18, 1176 (1998).
4. M. S. Espuelas, P. Legrand, P. M. Loiseau, C. Bories, G. Barratt, and J. M. Irache, In vitro antileishmanial activity of amphotericin B loaded in poly(epsilon-caprolactone) nanospheres. J. Drug Target 10, 593, (2002).